Consider DUPIXENT® in your patients with severe asthma characterized by type 2/eosinophilic phenotype or OCS-dependent asthma1

Studied in a clinical trial program that enrolled 2,888 adult and adolescent patients aged 12 years and older1

Table showing the patient profiles for three hypothetical patients. 

Danielle is 24 years old and was diagnosed with asthma as a child. Her blood EOS levels are 155 cells per microlitre. Her total IgE is 170 IU per millilitre. Her baseline FeNO is 35 parts per billion. She experiences at least 1 exacerbation annually. In terms of lung function, her FEV1 is 60%. She’s on high-dose ICS/LABA, and she is allergic to dust mites and cats. Andrew is 46 years old and has adult-onset asthma. His blood EOS levels are 350 cells per microlitre. His total IgE is 430 IU per millilitre. His baseline FeNO is 55 parts per billion. He experiences at least 2 exacerbations annually. In terms of lung function, his FEV1 is 60%. He’s on high-dose ICS/LABA and has a history of chronic rhinosinusitis with nasal polyps. Julie is 60 years old and has severe, oral corticosteroid-dependent asthma. Her blood EOS levels are 310 cells per microlitre. Her total IgE is 380 IU per millilitre. Her baseline FeNO is 20 parts per billion. She experiences at least 2 exacerbations annually. In terms of lung function, her FEV1 is 50%. She’s on high-dose ICS/LABA plus daily corticosteroids. She has a history of atopic dermatitis.

CRSwNP=chronic rhinosinusitis with nasal polyposis; EOS=blood eosinophil; FeNO=fraction of exhaled nitric oxide; FEV1=forced expiratory volume in 1 second; ICS=inhaled corticosteroid; IgE= immunoglobulin E; LABA=long-acting β2-agonist; OCS=oral corticosteroid.
* Not actual DUPIXENT® patients. May not be representative of the general population.

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.

Freedom support program logo.

Freedom Support Program

Find out what the Freedom Support Program can bring to your patients and how you can help them access it.


Sanofi Regeneron Logo

DUPIXENT® (dupilumab injection) logo


DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300228
Last updated: 06/2023


Innovative Medicines Canada logo PAAB logo